Duration 5min, Q&A 3min
Nanocomposite to Boost Drug Delivery of Ketorolac Eye Drop
The biological half-life of KT is 4 to 6 hours. Therefore frequent dosing is necessary to sustain the action of drug with a possibility of patient non-compliance while used for some of the inflammatory conditions of both anterior & posterior segment of eye.
In the present study, chitosan-Gelatin has been blended with Cloisite 30 B which is organically modified sodium in MMT with quaternary ammonium salt (the organic modifier in Cloisite 30B for the controlled release of ketorolac which can open up new dimension to use of Ketorolac eye drop
Chitosan (CS) (Degree of Deacetylation 98‰ determined by 1H-NMR and Molecular Weight 13.45 _104 Da) was purchased from India Sea Foods, Kerela, India. Gelatin (Type B, extracted from bovine skin) was purchased from Sigma Chemical. (St.Louis, MO). Cloisite 30 B was procured from Southern Clay Products. Ketorolac was a generous gift from Sun pharmaceuticals Industries limited, Gujrat
Chitosan-Gelatin/montmorillonite Cloisite 30 B (MMT) hybrid nanocomposites were prepared by blending chitosan-Gelatin with Cloisite 30 B in aqueous solution. The nano composites were characterized by using FTIR, SEM and XRD analysis. The drug release kinetics were investigated using ketorolac as the drug.
Results and Conclusion
The kinetics of the drug delivery system has been systematically studied. Drug release kinetics was analyzed by plotting the cumulative release data vs. time by fitting to an exponential equation which indicated the non-Fickian type of kinetics. The drug release was investigated at different pH medium and it was found that the drug release depends upon the pH medium as well as the nature of matrix.The controlled release of drug will help in reducing the frequent application of drug & effective penetration to posterior segment of eye
[ Keyword ]
Ketorolac / Drug delivery / Gelatin / Cloisite 30 B / Chitosan
[ Conflict of Interest ]